Conclusion: Lower tumor grade, tumor multifocality, concomitant CIS and tumors located in the lower ureter tend to be predictive for bladder recurrence after nephroureterectomy, although the underlying mechanism is not fully elucidated, and the scoring system could help risk stratification. Most recurrent tumors could be treated by transurethral resection and there were two peaks for recurrence, which is probably related to the mechanisms and may be unique to the Chinese population.
Introduction
Radical nephroureterectomy with excision of the bladder cuff is the gold standard treatment for localized upper tract urothelial carcinomas (UTUC). 1 The reported recurrence rate within the bladder after treatment of a primary UTUC is about 20e50%. 2e13 Several studies have attempted to delineate the clinical and pathological criteria for predicting such recurrences. 2e13 However, most investigations analyzed a comparatively small number of patients, and to our knowledge, there are few published reports from research centers in China. Chinese herbs are mainly consumed in this cohort of population and have been proven to be related to urothelial carcinoma, 14 and the incidence of UTUCs in the Chinese population is different from that of the Western population, although the mechanism related to the ethnic difference is still unknown. Chinese UTUC patients are more likely to be female and females are less likely to be in a more advanced pathologic stage than males. 15 The recurrence pattern and predictive factors might be different and experience from Chinese centers could help understand the recurrence mechanism. We therefore conducted this study based on data from a nationwide high volume center in China, in order to identify these factors in this unique population.
Materials and methods
The follow-up data of patients who were treated at Peking University First Hospital, Beijing, China for newly diagnosed UTUC from 2000 to 2010 was reviewed. Among the 631 patients with complete follow-up, 193 were excluded from the study: 71 had concomitant/previous bladder tumors, 25 had bilateral synchronous UTUCs, 54 underwent other surgeries instead of radical nephroureterectomy, 39 had a follow-up period < 12 months, two had metastasis disease, and two had a positive surgical margin. The remaining 438 patients were included in this study, and none of these patients received preoperative chemotherapy, although for some patients, adjuvant chemotherapy or radiotherapy was administered when evidence of distant metastasis or retroperitoneal recurrence was documented.
All patients were diagnosed by computed tomography, urologic ultrasound, magnetic resonance imaging (MRI), and in some patients, ureteroscopy with or without biopsy. Chest X-ray and preoperative cystoscopy were performed in all patients to rule out metastasis and concomitant bladder tumor. Urinary cytology specimens included voided specimens, catheterized bladder specimens, and selective ureteral washings. Surgical approaches included retroperitoneal open or laparoscopic nephroureterectomy. The ureter was ligated immediately after the control of the renal artery without dissecting around the kidney in all cases (for a tumor located in the lower ureter, the ureter was ligated in the proximal site of the tumor). Complete distal ureter and bladder cuff were removed entirely by extravesical dissection of the distal ureter and the intramural portion within the bladder wall through an open Gibson incision. Dissection of regional lymph nodes was performed in patients with suspicious lymph node invasion on preoperative imaging studies, or those suspected of having enlarged nodes during intraoperative inspection. All patients underwent surgery within 2 months after the occurrence of symptoms.
The follow-up regimen of affected patients included cystoscopy every 3 months for the first 2 years; cystoscopy intervals were extended to 1 year thereafter. Chest X-ray, serum creatine, abdominal ultrasound, and MRI or computed tomography were examined at the same time. We defined bladder recurrence as finding a subsequent bladder tumor during cystoscopy and confirmed it by pathology. The time of first bladder recurrence was used as the endpoint for the study. The follow-up of patients without tumor recurrence was censored to the date of their last visit. In case of death not related to the bladder cancer, follow-up was censored to the date of death.
Estimated glomerular filtration rate (eGFR) was calculated with the modified glomerular filtration rate estimating equation for Chinese patients. 16 Positive cytology was indicative of malignancy and the presence of atypical cells that were highly suggestive of urothelial carcinoma. Negative cytology was defined as no evidence of atypia, atypia without mention of malignancy, or scant cellular material. Based on the site of the dominant lesion, tumor location was defined as renal pelvis or ureter, and ureter was classified as the upper ureter (above the upper border of the sacrum), the middle ureter (from the upper to the lower border of the sacrum), and the lower ureter (below the lower border of the sacrum). 17 Tumor multifocality was defined as the synchronous presence of two or more pathologically confirmed macroscopic tumors in any location.
All statistical tests were performed with SPSS version 20.0 (IBM Corp, Armonk, NY, USA); statistical significance was set at p < 0.05. Univariate analysis using the log-rank test and multivariate analysis using Cox's proportional hazards regression model were used. The Pearson test and the Chi-square test were used to test the distribution of categorical variables. Only variables significant by univariate analysis were considered for the multivariate analysis.
According to the sum of ln(hazard ratio) of each risk factor (which is equal to the coefficient in Cox regression), a risk factor-based stratification model is proposed. 2 
Results
The demographic information of these patients is summarized in Table 1 . The median follow-up time was 45 months (range: 12e144 months). The median patient age was 66 years (range: 20e88 years). The distribution of UTUC pathological stage in this cohort was pTa, pT1, pT2, pT3, and pT4 in 22 (5.0%) patients, 131 (29.9%) patients, 166 (37.9%) patients, 116 (26.5%), and three (0.7%) patients, respectively. Pathological Grades 1e3 tumors were present in 15 (3.4%) individuals, 264 (60.3%) individuals, and 159 (36.3%) individuals, respectively. Multiple tumors were present in 82 patients (18.7%).
Pathology confirmed 135 patients (30.8%) with intravesical recurrence. The median interval of bladder recurrence was 15 months (range: 2.0e98.0 months). Ninetyseven of 135 (71.8%) bladder recurrences were diagnosed within 2 years after the primary operation. The exact number of recurrent cases within different months after surgery are shown in Fig. 1 . The two peaks for recurrence are 4e6 months and 17e19 months.
After first bladder recurrence, 118 (87.4%) patients received transurethral resection of bladder tumor (14 underwent total cystectomy for multiple recurrence or bladder tumor progression later during follow-up), seven patients received total cystectomy, one patient received partial cystectomy, one patient was treated with radiation therapy, and therapy modality was unclear for the remaining eight patients.
In the univariate analysis (Table 2) , tumor multifocality (p Z 0.004), lower tumor grade (p Z 0.010), tumor located in the lower ureter (p Z 0.005), and concomitant carcinoma in situ (CIS) (p Z 0.024) were predictive factors for bladder recurrence (Fig. 2 ). Rerunning the dataset by comparing Grades G1 and G2 with Grade G3 did not change the statistical significance of the tumor grade (p Z 0.003). Rerunning the dataset by comparing a tumor located in the ureter with a tumor located in the pelvis did not reach a significant difference (p Z 0.082). Other parameters, including sex, renal function, and tumor stage, were not related to an increased risk of intravesical recurrence. In multivariate analysis (Table 3) , tumor multifocality, lower tumor grade, tumor located in the lower ureter, and concomitant CIS remained the prognostic factors for recurrence. To construct the risk stratification model with consideration of all coefficients, we defined each score as the approximate value of 2 Â ln(hazard ratio of each factor) þ constant. Finally, the constant value was defined as two, to help calculations, and each risk factor was scored as follows: tumor Grade 1 Z two points, tumor Grade 2 Z one point, tumor Grade 3 Z zero points; multiple tumors Z three points, single tumor Z two points; presence of CIS Z four points, absence of CIS Z two points; tumor located in the lower ureter Z three points, and in other positions Z two points. All 438 patients were divided into four risk groups (low, low-intermediate, high-intermediate, or high) according to the sum of their risk factors score (6, 7, 8 , and 9 or more, respectively). There was a significant difference in bladder recurrence-free survival between the three risk groups with p < 0.001 (Fig. 3) .
When the risk factors for early recurrence and late recurrence were compared (we set the cut-off as 15 months according to the median recurrence interval, by which the two peaks were located in different groups), the only difference was the proportion of cases with concomitant CIS (Table 4) .
There were 71 deaths (16.2%) altogether during followup (including 46 cancer specific deaths), and bladder recurrence developed in 23 of this cohort of patients. If we exclude those patients who died during follow-up without bladder recurrence, multifocality, and tumor located in the lower ureter remained risk factors (p Z 0.007 and p Z 0.004, respectively). Lower tumor grade and concomitant CIS were nearly significant (p Z 0.061 and p Z 0.054, respectively). By log-rank test, no differences were found between patients with or without bladder recurrence in terms of cancer specific survival (p Z 0.796), or overall survival (p Z 0.897).
Discussion
Recurrent bladder tumors after nephroureterectomy require transurethral resection, which is associated with Figure 1 Number of bladder recurrence patients in different time intervals after surgery. 2e13 Most of them covered <300 cases, and cases with conservative surgery modality or follow-up of <12 months were included in some articles. We evaluated most of the previously published predictive variables. History of bladder tumor was believed to be relevant to bladder recurrence after nephroureterectomy in some studies, 8, 12 but we think that it is proper to exclude those with a prior history of bladder cancer and/or those with concomitant bladder cancer from this series, as bladder tumor growth might represent recurrent local disease unrelated to upper urinary tract carcinoma.
Multifocality is proven to be related to intravesical recurrence in several investigations 2, 3, 9, 12 and is currently the most reliable risk factor for predicting bladder tumor recurrence. Synchronous/metachronous bladder cancer could be attributed as an aspect of multifocal urothelial cancer.
Ureteral involvement of the primary tumor is also a significant risk factor in previous reports.
5,6,13 Zigeuner et al 5 concluded that the higher urine flow rate and intraluminal pressure in the ureter lead to increased mechanical irritation and possible subsequent detachment of tumor cells. Tumors in the pelvis tend to have a better bladder recurrence-free survival in our study (p Z 0.082) but statistical differences only exist between tumors in the lower ureter and other lesions. Two previous papers showed a positive correlation between lower ureteral lesions and bladder recurrence. 4, 6 The early ligation in the distal site of tumors located in other lesions might play an important role in preventing tumor implantation.
Two studies have reported the association of concomitant CIS with bladder recurrence. 7, 12 Pieras et al 7 thought that the presence of CIS indicated that, besides the primary tumor, there might be changes in the mucosa adjacent to and further from the initial tumor, which could be the origin of the appearance of new tumors; it reflects a premalignant state of the entire urinary bladder surface. However, the prevalence of concomitant CIS varied in different studies on UTUC, 7, 12, 19 and the number of patients with CIS in our study is limited, which hampered the significance.
It is relatively difficult to explain the negative implications of a lower tumor grade for bladder cancer recurrence. Because tumor grade is strictly related to cancer aggressiveness and tumor stage, it represents a well-established predictor of cancer-related survival, 20 but there is no consensus on the possible influence of tumor grade on subsequent bladder cancer recurrence. Bloom et al 21 agreed with our study that lower tumor grade related to bladder recurrence, whereas Zigeuner et al 5 and Huang et al 10 found a correlation between higher tumor grade and intravesical recurrence. It is notable that tumor stage had no negative role for bladder recurrence in our research and the conclusions are also controversial in previous trials; lower tumor stage 2,3,21 as well as higher tumor stage 7, 9, 13 was proved to be related to intravesical recurrence in different studies.
In our research, we consider two potential reasons behind the predictive role of lower grade on bladder recurrence. On the one hand, higher tumor grade is related to more cancer-specific deaths. Patients may die from tumor dissemination before bladder tumor development is detectable. 5 After excluding those patients who died during follow-up without bladder recurrence, the influence of tumor grade on bladder recurrence was not that significant, with p Z 0.061. On the other hand, a higher tumor grade is related to cancer aggressiveness and distant metastasis, but the mechanism for bladder recurrence might be different. Hisataki et al 9 proposed that patients with a high risk of intravesical recurrence do not necessarily have a risk of progression to muscle invasion. Besides, the determination of tumor grade according to WHO 1973 (not the classification of WHO/International Society of Urologic Pathology) might also contribute to this result.
The field cancerization hypothesis 22 and intraluminal seeding 23 are currently the two main concepts to explain the multifocality of urothelial cancer and the recurrent bladder tumor, and the two mechanisms could co-exist. 24 Independent multiclonal tumor development after carcinogen exposure of the entire urothelial and intraluminal implantation, followed by single progenitor cell induced clonally evolution are the mechanisms suggested. We consider that there might be a possible correlation between lower grade and the molecular recurrent mechanism; carcinogen exposure to an entire urothelial layer might easily induce carcinoma with low tumor grade, or a weakly aggressive low grade tumor cell might easily drop from the urothelial layer to cause intraluminal seeding. However, biochemical study is required to further clarify these propositions. The median interval of bladder recurrence was 15 months, and >70% recurrence occurred 2 years after nephroureterectomy. However, with surveillance, the latest intravesical recurrence was found 98 months after surgery, which means that the period of high risk for recurrence is about 2 years after nephroureterectomy; after this, the hazard continued over a long period of time as previously reported. 11 The two peaks for recurrence have never been reported, and they might be correlated to the mechanisms for recurrence.
Regarding intravesical recurrence after primary bladder cancer, Hinotsu et al 25 proposed that the early recurrence be considered the "true recurrence", and the late recurrence be explained as "new second recurrence". Takaoka et al 11 also proposed the "two phase" regarding intravesical recurrence after UTUC, and that the early recurrent pattern might reflect the seeding hypothesis, whereas the late one reflects the field cancerization hypothesis. By comparison of early and late recurrence in our study, patients with CIS tended to develop a late recurrence, and because the presence of CIS reflects a premalignant state of the entire urinary surface, 7 independent multiclonal tumor development (the field cancerization hypothesis) might play a dominant role in this cohort of patients. In addition, considering Chinese herbs are mainly consumed in this cohort of population and aristolochic acid might bring nephrotoxic and carcinogenic toxins to induce neoplasm of the whole urothelial field, 26 ,27 the recurrence mechanisms might be unique. This assumption of a relationship between the recurrence pattern and mechanism requires molecular genetic studies, and the discovery of a mechanism for recurrence would help to explain the clinicopathological factors for recurrence; also, molecular and histological markers could be useful in daily practice in the future. 28 Because most cancers that subsequently developed in the bladder could be managed by transurethral resection, and survival analysis indicates recurrent bladder tumor is not a poor prognostic factor, the surveillance and treatment of recurrent bladder tumor could be individualized.
Limitations of this study include the retrospective design and data collection, thus subject to selection and recall bias. The proportion of patients with G1 and concomitant CIS is too small, and only a few patients underwent lymph node dissection. The incidence of UTUCs in the Chinese population is much higher than that of the Western population and the biology may be different, and although the mechanism related to these ethnic differences is still not fully known, dietary exposure to toxins may play a major role. 29 Despite these limitations, our research is currently the largest single-center study on intravesical recurrence after nephroureterectomy in the Chinese population. Prospective investigations combining molecular genetic studies are required to help realize the exact mechanism for bladder recurrence and improve the predictive performance.
In conclusion, lower tumor grade, tumor multifocality, concomitant CIS, and tumors located in the lower ureter tend to be predictive for bladder recurrence after nephroureterectomy, although the underlying mechanism is not fully elucidated. The risk-stratification model may help clinicians in postoperative follow-up and adjuvant therapy. Most recurrent tumors could be treated by transurethral resection and there are two peaks for recurrence, which is probably related to the mechanisms of bladder cancer recurrence and may be unique for the Chinese population.
